Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients

Canadian Journal of Infectious Diseases

Volumn 14, Issue 4, 2003, Pages 201-205

  Baril, Jean Guy ^a   Lefebvre, Eric A ^b   Lalonde, Richard G ^c   Shafran, Stephen D ^d   Conway, Brian ^e  

^a Clinique Medicale du Quartier Latin   (Canada)

^b Clinique Medicale l'Actuel   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretroviral therapy; Nelfinavir; Non nucleoside reverse transcriptase inhibitors; Salvage therapy

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANEMIA; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; GLUCOSE INTOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUROPATHY; PANCREATITIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0142054947     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/309724     Document Type: Article

References (26)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
3. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998;12:1619-24.
4. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999;13:F35-43.
5. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-8.
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
7. Montaner JS, Reiss P, Cooper D, et al. A randomized, double blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-7.
8. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999;13:1873-80.
9. Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. February, 2002. 〈 www.hopkins-aids.edu/guidelines/adult/gl_adult.pdf〉 (Version current at June 9, 2003).
10. Yeni PG, Hammer S, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society - USA Panel. JAMA 2002;288:222-35.
11. Henry K, Lamarca A, Myers R, Chapman S. The safety of Viracept® (nelfinavir mesylate, NFV) in pivotal phase II/III double blind, randomized controlled trials as monotherapy and in combination with either d4T or AZT/3TC. 4th Conference on Retroviruses and Opportunistic Infections. Washington, June 22-26, 1997. (Abst 384)
12. Clendennin N, Quart B, Anderson R, Knowles M, Chang Y. Analysis of long-term virologic data from the VIRACEPT (nelfinavir mesylate, NFV) 511 protocol using 3 HIV-RNA assays. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1-5, 1998. (Abst 372)
13. Clumeck N. AVANTI 3: A randomized, double blind comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs. AZT/3TC/nelfinavir in anti-retroviral naive patients. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1-5, 1998. (Abst 8)
14. Seminari E, Maggiolo F, Villani P, et al. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors. J Acquir Immune Defic Syndr 1999;22:453-60.
15. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000;182:1375-84.
16. Hammer S, Mellors J, Vaida F, et al. Randomized, placebo-controlled trial of saquinavir (SQV) sgc, indinavir (IDV) or nelfinavir (NFV) in combination with amprenavir (APV), abacavir (ABC), efavirenz (EFZ) and adefovir (ADV) in patients (pts) with protease inhibitor (PI) failure. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, January 30-February 2, 2000. (Abst LB7)
17. Hammer S, Squires K, Degruttola V, et al. Randomized trial of abacavir (ABC) & nelfinavir (NFV) in combination with efavirenz (EFV) and adefovir dipivoxil (ADV) as salvage therapy in patients with virologic failure receiving indinavir (IDV). 6th Conference on Retroviruses and Opportunistic Infections. Chicago, January 31-February 4, 1999. (Abst 490)
18. Arrizabalaga J, Iribarren JA, Rodriguez-Arrondo FJ, Von Wichmann MA. Salvage therapy with ddI + hydroxyurea (HU) + efavirenz (EFV) + nelfinavir (NFV) in patients who had previously failed indinavir (IDV)/ritonavir (RIT) regimens: 24 Weeks follow-up. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 26-29, 1999. (Abst 2206)
19. Danner S, Brun S, Sylte J, et al. Kaletra (lopinavir/ritonavir) and efavirenz: 72 Week safety/efficacy evaluation and phenotypic/genotypic breakpoints in multiple PI experienced patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December 16-19, 2001. (Abst 1-1925)
20. Moyle G. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. Drugs 2001;61:19-26.
21. De Clerq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in therapy of HIV-1 infection. Antiviral Res 1998;38:153-79.
22. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor - containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999;179:1375-81.
23. National AIDS Treatment Advocacy Project NNRTI - Non-cleoside reverse transcriptase inhibitor section. NATAP reports 1998;1:5. 〈 www.natap.org/1998/98reports/natap_reports3.5.htm〉 (Version current at June 9, 2003).
24. Cox SR, Schneck DW, Herman BD, et al. Delavirdine (DLV) and nelfinavir (NFV): A pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1-5, 1998. (Abst 345)
25. Fiske WD, Bendek IH, White SJ, Pepperess KA, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir (NFV) in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1-5, 1998. (Abst 349)
26. Casado JL, Dronda F, Hertogs K, et al. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir and saquinavir as salvage regimen after ritonavir or indinavir failure. AIDS Res Hum Retroviruses 2001;17:93-8.